Cardionovum

Be up
to date.

Latest press release

Late-Breaking Xlimit RCT data presented at CSC Congress demonstrate an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES.

Bonn, Germany. November 16, 2022 – Data presented at Innovation session today at the CSC 2022 congress demonstrated an equivalent performance of the Xlimus® DES in terms of OCT derived endpoints than the Synergy™ DES, including Neointimal Volume and Neointimal Volume weighted by length at 6 months. Secondary endpoints, including other OCT parameters, such as in-stent Minimum Lumen Area (MLA) and percentage of strut coverage as well as clinical endpoints, showed no significant differences between the two groups in any of the evaluated parameters within the Xlimit RCT.

Learn more >>

Prof. Matteo Tozzi discusses about new data bolster safety and effectiveness of Safepax®

Prof. Matteo Tozzi (Varese, Italy) speaks to Vascular News at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2022 annual meeting in Barcelona (Spain) about his new study that analyzes the concentrations of paclitaxel in the bloodstream after the use of a Drug-Coated Balloons (DCBs) in AVFs.

Learn more >>

CARDIONOVUM® announces regulatory approval of APERTO® OTW in Mexico

We are proud to announce that we have received the authorization by the Secretaria de Salud and COFEPRIS to distribute APERTO® OTW in Mexico.

Learn more >>

Cardionovum® announces First Procedure in Hyper II International Clinical Trial.

CARDIONOVUM® today announced the enrollment of the first patient in the International Hyper II Clinical Study

Learn more >>

CARDIONOVUM® announces the first Signature RCT patient enrollment

On June 8th, in Sankt Gertrauden hospital in Berlin, Germany, the first Signature RCT patient has been enrolled

Learn more >>

CARDIONOVUM announces completion of patients enrolment in XLIMIT Trial

Trial designed to evaluate non inferiority of XLIMUS DES vs SYNERGY EES in terms of reendothelialization assessed with OCT in patients undergoing percutaneous coronary intervention

Learn more >>

Upcoming events

Currently there are no events.

Latest events

Cardionovum® at CSC 2022

Cardionovum® is delighted to announce the release of the XLIMIT Randomized Clinical Trial data.

  • Dr. Luca Testa, the PI of the study, will share his findings on the topic of:
    “    OCT-based analysis of XLIMUS® DES vs. SYNERGY DES”

    Thursday 16th November at 17:45h
    SALA MADRID 1-2

Location:

Hotel Riu Plaza España
Calle Gran Vía, 84,
28013, Madrid, Spain

You are welcome to visit us at booth #2

Date: Nov 16, 2022–Nov 17, 2022

Learn more >>

Cardionovum at GISE 2022

Cardionovum invites you to attend a scientific session:

  • GAP IN KNOWLEDGE:
    Role of drug-coated balloons in de novo lesions

    Dr Alfonso Ielasi - the PI of the Hyper study - will share his findings on the topic of:
    Clinical scenario: “A patient treated with a hybrid DES-DEB strategy”

    Thursday 11st October at 14:30h
    ROOM AMBER 5-6

Location:

Allianz MiCo - Milano Congressi
South Wing
Viale Eginardo - Gate 2
20149 Milano, Italy

You are welcome to visit us at booth #45, 2nd Floor (ALA SUD)

Date: Oct 11, 2022–Oct 15, 2022

Learn more >>

Cardionovum at CIRSE 2022

Cardionovum invites you to visit us at booth #70

Location:

CCIB Conference Center
Plaça de Willy Brandt, 11-14,
08019 Barcelona, Spain
 

Date: Sep 10, 2022–Sep 15, 2022

go top